Oncology Brothers: Practice-Changing Cancer Discussions

Welcome to the Oncology Brothers podcast! In this episode, we dived into the latest advancements in HER2-targeted therapies for upper gastrointestinal malignancies, with Drs. Shruti Patel and Samuel Cytryn.   Join us as we discussed: The recent approval of zanidatamab and its implications for HER2-positive esophageal and gastric adenocarcinoma The role of trastuzumab in treatment and its associated side effects, including cardiotoxicity and infusion reactions Addressing different dose used for trastuzumab deruxtecan (T-DXd) in upper GI space, along with important side effect profile to keep in mind The importance of shared decision-making in treatment options and the impact of dosing strategies on patient outcomes   We also covered the critical need for biomarker-driven treatment approaches, including HER2 status and PD-L1 scores, and how these factors influence therapy choices.   Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o  Follow us on social media:  ⁠X/Twitter: https://x.com/oncbrothers  ⁠Instagram: https://www.instagram.com/oncbrothers  Website: https://oncbrothers.com/    Tune in for an informative discussion that bridges the gap between research and clinical practice, ensuring that patients receive the best care possible. Don't forget to like, subscribe, and hit the notification bell for more episodes! #HER2positive, #UpperGICancer, #Zanidatamab, #Trastuzumab, #TDXd, #OncologyBrothers

Welcome to the Oncology Brothers podcast! In this episode, we were joined by Dr. Samuel Klempner, a GI medical oncologist from the Massachusetts General Hospital, to discuss the evolving treatment landscape for upper gastrointestinal cancers, specifically esophageal, gastroesophageal junction (GEJ), and gastric adenocarcinoma.   During our discussion we touched on: The treatment algorithm for localized disease, including the shift from local therapy to a combination of systemic and local treatments The current standard of care, which includes perioperative durvalumab with the FLOT regimen and surgery The role of chemoradiation therapy for patients who are not surgical candidates and the nuances of managing residual disease The importance of biomarker-driven treatment in metastatic disease, focusing on HER2 status, PD-L1 scores, and CLDN18.2 expression The latest advancement, the approval of zanidatamab and clinical implications for treatment strategies Management of side effects associated with these therapies and the importance of patient quality of life   Whether you're a healthcare professional or someone interested in the latest in cancer care, this episode provides valuable insights into the complexities of treating upper GI cancers.   Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o    Follow us on social media: X/Twitter: https://x.com/oncbrothers  ⁠Instagram: https://www.instagram.com/oncbrothers  Website: https://oncbrothers.com/    Don't forget to like, subscribe, and hit the notification bell for more episodes from the Oncology Brothers! #UpperGICancer, #GastricCancer, #Zanidatamab, #Zolbetuximab, #OncologyBrothers

In this episode of the Oncology Brothers podcast, we welcomed Dr. Jonathan Friedberg, a leading lymphoma expert, to discuss modern treatment approaches for follicular lymphoma and mantle cell lymphoma.   Join us as we explored: The diagnostic workup for follicular lymphoma, including the role of bone marrow biopsy and staging imaging Treatment strategies for early-stage and symptomatic follicular lymphoma, including rituximab, obinutuzumab, and chemotherapy-based approaches The evolving role of maintenance therapy and what recent studies have shown about progression-free and overall survival New treatment options in relapsed/refractory follicular lymphoma, including tafasitamab and epcoritamab The importance of TP53 testing in mantle cell lymphoma and the evolving role of BTK inhibitors in frontline treatment The role of CAR T-cell therapy and bispecific antibodies in the evolving lymphoma treatment landscape   This discussion provided practical insights into current treatment algorithms and emerging strategies for patients with follicular lymphoma and mantle cell lymphoma.   Whether you're a hematologist, oncologist, advanced practice provider, nurse, pharmacist, trainee, or healthcare professional interested in lymphoma care, this episode offers an expert perspective on the rapidly evolving treatment landscape.   If you found this discussion valuable, please like the video, subscribe to the Oncology Brothers, and share your thoughts in the comments.   Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o  Follow us on social media: ⁠X/Twitter: https://x.com/oncbrothers  ⁠Instagram: https://www.instagram.com/oncbrothers  Website: https://oncbrothers.com/    Subscribe for more expert discussions on hematology, oncology, lymphoma, immunotherapy, cellular therapy, targeted therapy, and advances in cancer care. #FollicularLymphoma #MantleCellLymphoma #Lymphoma #Hematology #OncologyBrothers

In this episode of the Oncology Brothers podcast we had a chance to discuss the current treatment landscape for diffuse large B-cell lymphoma (DLBCL) with Dr. Mazyar Shadman, from the Fred Hutch Cancer Center.   We dived deep into frontline treatment options, including R-CHOP and polatuzumab-based regimens, and explored how to effectively risk stratify patients using the International Prognostic Index (IPI) score and the Hans algorithm. Dr. Shadman shared insights on the use of CAR T-cell therapy in both early and late relapsed settings, discussing the differences between axicabtagene ciloleucel (axi-cel) and lisocabtagene maraleucel (liso-cel), and the importance of bridging and holding therapies.   Key topics covered in this episode: Frontline treatment options for DLBCL The role of polatuzumab in early-stage disease Treatment paradigms for advanced-stage DLBCL CAR T-cell therapy: who should receive it and when The importance of community and tertiary care partnerships in improving patient access to innovative therapies   Join us for an informative discussion that highlights the evolving landscape of DLBCL treatment and the critical role of collaboration in oncology care.   Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o   Follow us on social media: X/Twitter: https://x.com/oncbrothers  ⁠Instagram: https://www.instagram.com/oncbrothers  Website: https://oncbrothers.com/    Don't forget to like, subscribe, and share your thoughts in the comments! #DLBCL, #CARTtherapy, #RCHOP, #Polatuzumab, #OncologyBrothers

Welcome to the Oncology Brothers podcast! In this episode, we dove deep into the groundbreaking advancements in pancreatic cancer treatment, focusing on the recent approval of daraxonrasib.   Join us as we welcome Mark Goldsmith, MD, PhD, CEO of Revolution Medicines, who shared his inspiring journey from clinical practice to the biotech industry. Discover the challenges and triumphs behind bringing this first-in-class drug to market, and learn about the significant impact it has on patient outcomes.   Keypoints: Daraxonrasib is a first-in-class RAS inhibitor approved for the treatment of pancreatic cancer, targeting a mutation present in over 90% of cases. The drug's development represents a major shift in pancreatic cancer, moving from a historically untreatable disease to a promising target for precision medicine. Early clinical trial results demonstrated remarkable tumor shrinkage, driving urgency to bring the therapy to patients. Management of side effects, including rash and gastrointestinal issues, is essential for optimal patient outcomes. Ensuring patient access—despite high treatment costs—remains a priority, with patient assistance programs and insurance navigation support in place. Future directions include combination therapies and the goal of transforming pancreatic cancer into a manageable chronic disease.   We discussed the critical gaps between academic research and community practice, the importance of understanding side effects, and the financial implications of new therapies. Dr. Goldsmith also highlighted the future of pancreatic cancer treatment and the ongoing commitment to improving patient care.   Whether you're a healthcare professional, a patient, or simply interested in the latest in oncology, this episode is packed with valuable insights and information.   Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o  Follow us on social media: ⁠X/Twitter: https://x.com/oncbrothers  Instagram: https://www.instagram.com/oncbrothers  Website: https://oncbrothers.com/    Don't forget to like, subscribe, and hit the notification bell for more episodes on the latest in cancer treatment and research! #PancreaticCancer, #Daraxonrasib, #RASinhibitor, #DrugDevelopment, #OncologyBrothers